Yang Shaolong, Liu Juanyu, Khe Jia Siang, Lu Alvin Jiunn Hieng, Lim Vuanghao
Advanced Medical and Dental Institute, Universiti Sains Malaysia, Bertam Kepala Batas, Penang, Malaysia; School of Nursing, Zhengzhou Railway Vocational & Technical College, Pengcheng Avenue, Zhengdong New District, Zhengzhou, Henan Province, China.
Department of Orthopaedic Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; Department of Biomedical Science, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Biomol Biomed. 2025 Jul 31;25(8):1691-1708. doi: 10.17305/bb.2025.12144.
Hepatic ischemia-reperfusion injury, fatty liver, liver fibrosis, liver peroxidative injury, and drug-induced liver injury are among the most common liver diseases. Mesenchymal stem cells (MSCs) possess multi-lineage differentiation potential and immunomodulatory functions. In the treatment of liver injury, MSCs can promote repair through homing effects, direct differentiation into hepatocyte-like cells (HLCs), immunomodulation, and anti-fibrotic mechanisms. Clinically, MSCs contribute to liver injury repair either directly or indirectly via the secretion of exosomes. Beyond their reparative role, MSC-derived exosomes can also serve as molecular biomarkers for the diagnosis and prognosis of liver diseases. Establishing higher-quality standards, robust auditing and evaluation systems, and conducting deeper mechanistic studies are essential prerequisites for the future clinical application of MSCs in the treatment of liver diseases.
肝缺血再灌注损伤、脂肪肝、肝纤维化、肝过氧化损伤和药物性肝损伤是最常见的肝脏疾病。间充质干细胞（MSCs）具有多向分化潜能和免疫调节功能。在肝损伤治疗中，间充质干细胞可通过归巢效应、直接分化为肝细胞样细胞（HLCs）、免疫调节和抗纤维化机制促进修复。临床上，间充质干细胞通过分泌外泌体直接或间接促进肝损伤修复。除了其修复作用外，间充质干细胞来源的外泌体还可作为肝脏疾病诊断和预后的分子生物标志物。建立更高质量标准、健全的审核和评估体系以及开展更深入的机制研究是间充质干细胞未来在肝脏疾病治疗中临床应用的必要前提。
